Medine.co.uk

Megacal-M Solution For Injection

Revised: January 2015

(Minor Typographical errors)

AN: 01339/2007


SUMMARY OF PRODUCT CHARACTERISTICS


1. NAME OF THE VETERINARY MEDICINAL PRODUCT


Megacal-M Solution for Injection


2. QUALITATIVE AND QUANTITATIVE COMPOSITION


Active Substance:


Calcium (as Calcium Gluconate) 4.6g/100ml

Magnesium (as Magnesium Hypophosphite) 0.8g/100ml


Excipient:


Boric Acid 10.0g/100ml


For the full list of excipients, see section 6.1


3. PHARMACEUTICAL FORM


Solution for injection

A colourless to pale yellow solution


4. CLINICAL PARTICULARS


4.1 Target Species:

Cattle


Indications for use, specifying the target species


For treatment of hypocalcaemia and as an aid in raising blood magnesium levels where a deficiency may be expected.

4.3 Contra-indications


Known hypersensitivity to the to the active ingredients.

Known cases of cardiac arrhythmia or severe toxaemia


4.4 Special warnings for each target species


The product should be administered with care particularly where concurrent toxaemia exists. In recumbent cows with poor peripheral circulation, administer appropriate calcium therapy intravenously.


4.5 Special precautions for use


Warm the product to body temperature before administration.

When the intravenous route is being used, extreme caution must be taken to ensure slow administration.

This product does not contain an antimicrobial preservative. Any solution remaining in the vial after withdrawal of the required dose should be discarded.


Special precautions to be taken by the person administering the product to animals


Care should be taken to avoid accidental self-injection. If accidental self-injection occurs, seek medical advice.

Eye Contact: immediately flush the eye with copious amounts of clean running water.

Skin contact: Wash the affected area thoroughly. If irritation occurs seek medical advice.

Ingestion: If accidentally swallowed, seek urgent medical attention and show product label and / or pack insert to the doctor.

ADVICE TO DOCTOR: For treatment advice contact the National Poisons Information Service (NPIS) or your local Poisons Information Centre.


4.6 Adverse reactions (frequency and seriousness)


None known


4.7 Use during pregnancy, lactation or lay


Safe for use during pregnancy and lactation


4.8 Interaction with other medicinal products and other forms of interaction


None known.


4.9 Amounts to be administered and administration route


By subcutaneous or slowintravenous injection.

Cattle – 100 - 200ml.

Large volumes should be divided between multiple sites. Massage sites gently.


4.10 Overdose (symptoms, emergency procedures, antidotes), if necessary


The product is for treatment of acute deficiency in a life threatening situation and overdosage within the recommended guidelines is unlikely.


4.11 Withdrawal period(s)


Meat – Zero days

Milk – Zero hours


5. PHARMACOLOGICAL PROPERTIES


This product is intended to restore blood calcium levels in cases of hypocalcaemia.


6. PHARMACEUTICAL PARTICULARS


6.1 List of Excipients


Boric Acid

Water for Injection

Sodium Hydroxide (For pH adjustment)

Acetic Acid (For pH adjustment)


6.2 Major incompatibilities


None known


6.3 Shelf life


Shelf life of the veterinary medicinal product as packaged for sale:

3 years.


Special precautions for storage


Store below 25°C. Protect from light.


Nature and composition of immediate packaging


A 100ml clear glass vial with nitryl rubber bung and gold seal containing a clear, colourless to pale yellow sterile solution


Special precautions for the disposal of unused veterinary medicinal product or waste materials derived from the use of such products, if appropriate


Any unused veterinary medicinal product or waste materials derived from such veterinary medicinal products should be disposed if in accordance with local requirements.



7. MARKETING AUTHORISATION HOLDER


Ballinskelligs Veterinary Products,

Ballinskelligs,

Co. Kerry,

Ireland.


8. MARKETING AUTHORISATION NUMBER


Vm 12828/4000


9. DATE OF FIRST AUTHORISATION


01 February 1999


10. DATE OF REVISION OF THE TEXT


January 2015





Approved: 29 January 2015

Page 4 of 4